A carregar...
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target
Invasive bladder cancer has high morbidity and nearly uniform mortality when metastatic, with no therapeutic improvement in many years. Although chemotherapy combined with Chk1 inhibition has been investigated in several cancer types in which TP53 mutation is seen, this combination treatment approac...
Na minha lista:
| Publicado no: | Mol Cancer Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4297264/ https://ncbi.nlm.nih.gov/pubmed/25349305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0622-T |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|